Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Total Flavonoids of Rhizoma Drynariae in Treating Rheumatoid Arthritis

Chen, Guang-Yao; Luo, Jing; Liu, Yi; Yu, Xin-bo; Liu, Xiao-Yu; Tao, Qing-Wen

doi:10.2147/dddt.s354946

Cited by 15 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 We have also found in other studies that TFRD can play a role in the treatment of rheumatoid arthritis by inhibiting the inflammatory response. 43 In this study, pathological assessment indicated that TFRD had chondro-protective effect in OA rat model.…”

Section: Discussionmentioning

confidence: 59%

Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway

Chen,

Liu,

Yan

et al. 2023

JIR

Self Cite

View full text Add to dashboard Cite

Previous clinical studies have found that total flavonoids of Rhizoma Drynariae (TFRD) have a good therapeutic effect on osteoarthritis (OA), but its therapeutic mechanism needs further research. Methods: OA rat model was established by Hulth method and was intervened by TFRD. Pathological assessments were conducted to assess the protective effect of TFRD on cartilage. Serum metabolomics and network pharmacology were detected to predict the mechanism of TFRD treating OA. In further experiments, molecular biology experiment was carried out to confirm the predicted mechanisms in vivo and in vitro. Results: TFRD can effectively reduce chondrocyte apoptosis and cartilage degeneration in OA model rats. Serum metabolomics revealed that the intervention effect may be closely related to arachidonic acid metabolism pathway. Network pharmacologic prediction showed that COX-2 was the key target of TFRD in treating OA, and its mechanism might be related with NFκB, apoptosis, AMPK and arachidonic acid metabolism pathway. In vivo experiments indicated that TFRD can inhibit the abnormal expression of COX-2 mRNA in OA model rats. In the in vitro studies, the expression of COX-2 mRNA and protein increased, AMPK phosphorylation was inhibited, and NFκB signaling pathway was activated in IL-1β-induced chondrocytes, and these changes can be reversed by TFRD. After the activation of AMPK signaling pathway or the block-down of NFκB signaling pathway, the effect of TFRD on COX-2 mRNA expression was significantly weakened. Conclusion: TFRD can inhibit COX-2-mediated arachidonic acid metabolites, and its mechanism is closely related to AMPK/NFκB pathway, which may be a key mechanism in the treatment of OA.

show abstract

Section: Discussionmentioning

confidence: 59%

Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway

Chen,

Liu,

Yan

et al. 2023

JIR

Self Cite

View full text Add to dashboard Cite

show abstract

“…In conclusion, the physiological functions of Th17 and Treg cells are antagonistic, and the differentiation of these two cells is regulated by the interaction of various cytokines. When antigen-driven inflammation persists, interconversion between Th17 and Treg may occur [ 55 ], since the cytokine network appears to favor the differentiation of Th17 cells while minimizing immunosuppressive Tregs [ 56 ]. This imbalance between pro- and anti-inflammatory forces persists in autoimmune pathologies such as pSS.…”

Section: Discussionmentioning

confidence: 99%

Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren’s syndrome

Liao,

He,

Huang

et al. 2024

BMC Immunol

Self Cite

View full text Add to dashboard Cite

Objective The study aimed to explore the mechanism of artemisinin in treating primary Sjögren’s syndrome (pSS) based on network pharmacology and experimental validation. Methods Relevant targets of the artemisinin and pSS-related targets were integrated by public databases online. An artemisinin-pSS network was constructed by Cytoscape. The genes of artemisinin regulating pSS were imported into STRING database to construct a protein-protein interaction (PPI) network in order to predict the key targets. The enrichment analyses were performed to predict the crucial mechanism and pathway of artemisinin against pSS. The active component of artemisinin underwent molecular docking with the key proteins. Artemisinin was administered intragastrically to SS-like NOD/Ltj mice to validate the efficacy and critical mechanisms. Results Network Pharmacology analysis revealed that artemisinin corresponded to 412 targets, and pSS related to 1495 genes. There were 40 intersection genes between artemisinin and pSS. KEGG indicated that therapeutic effects of artemisinin on pSS involves IL-17 signaling pathway, HIF-1 signaling pathway, apoptosis signaling pathway, Th17 cell differentiation, PI3K-Akt signaling pathway, and MAPK signaling pathway. Molecular docking results further showed that the artemisinin molecule had higher binding energy by combining with the key nodes in IL-17 signaling pathway. In vivo experiments suggested artemisinin can restored salivary gland secretory function and improve the level of glandular damage of NOD/Ltj mice. It contributed to the increase of regulatory T cells (Tregs) and the downregulated secretion of IL-17 in NOD/Ltj model. Conclusion The treatment of pSS with artemisinin is closely related to modulating the balance of Tregs and Th17 cells via T cell differentiation.

show abstract

“…SX active components screening on the IMPPAT (Indian Medicinal Plants, Phytochemicals and Therapeutics) ( https://cb.imsc.res.in/imppat/home ) database ( Mohanraj et al, 2018 ), the plant name “ S. xanthocarpum / virginianum ” was entered sequentially to retrieve the matching phytochemical substances and related information ( Murali et al, 2022 ). The screening conditions for obtaining the effective components and corresponding targets of each drug of SX were set according to the principle of pharmacokinetics (ADME), bioavailability score (BS) ≥ 0.3 and drug-likeness (DL) ≥ 0.18 ( Chen et al, 2022a , Chen et al, 2022b ) obtained from Swiss ADME ( https://www.swissadme.ch/ ) ( Ranjith and Ravikumar, 2019 ) and Molsoft L.L.C. (Drug-likeness prediction, https://molsoft.com/mprop/ ) ( Ahsan et al, 2011 ) respectively.…”

Section: Methodsmentioning

confidence: 99%

“…The Venn diagram ( https://bioinfogp.cnb.csic.es/tools/venny/ ) was filled with the screened SX phytoconstituent targets and PSO disease targets ( Chen et al, 2022a , Chen et al, 2022b ) and as prospective objectives for additional investigation, the intersection targets of active components in SX and PSO were gathered.…”

Section: Methodsmentioning

confidence: 99%

Multi-target mechanism of Solanum xanthocarpum for treatment of psoriasis based on network pharmacology and molecular docking

Sahu,

Madan,

Walia

et al. 2023

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Total Flavonoids of Rhizoma Drynariae in Treating Rheumatoid Arthritis

Cited by 15 publications

References 51 publications

Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway

Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway

Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren’s syndrome

Multi-target mechanism of Solanum xanthocarpum for treatment of psoriasis based on network pharmacology and molecular docking

Contact Info

Product

Resources

About